TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01169675
Drug: BIBW 2992 high dose 6 day
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
Study: NCT00510536
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose to be determined by investigator
Study: NCT00624936
Drug: Vidaza
Normalized name: Vidaza
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
Study: NCT00624936
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
Study: NCT03061136
Drug: Clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04404764
Drug: Nusinersen Injectable Product
Normalized name: nusinersen Injectable Product
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
Study: NCT00912743
Drug: olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg po bid continuously
Study: NCT01169675
Drug: BIBW 2992 low dose 6 day
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
Study: NCT00060242
Drug: fosbretabulin disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
Study: NCT02815332
Drug: BPX-01 Vehicle Topical Gel
Normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1 gram applied once daily for 12 weeks
Study: NCT01169675
Drug: BIBW 2992 medium dose 6 day
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
Study: NCT01169675
Drug: BIBW 2992 medium dose
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
Study: NCT00033358
Drug: medroxyprogesterone
Normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intramuscularly
Study: NCT00033358
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00033358
Drug: norgestrel
Normalized name: Norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02682693
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 120 mg every 4 weeks for 6 cycles
Study: NCT02682693
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
Study: NCT02682693
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
Study: NCT02682693
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
Study: NCT02682693
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
Study: NCT02682693
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
Study: NCT03259464
Drug: BI 685509
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sequential dose groups
Study: NCT01834742
Drug: Moviprep
Normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
Study: NCT00936442
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
Study: NCT01942681
Drug: Propiverine Hydrochloride
Normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrate Propiverine Hydrochloride for 12 weeks
Study: NCT03829124
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 10mg/ml IV push slowly 0.5-2mg/kg
Study: NCT03829124
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
Study: NCT00445679
Drug: DVS SR
Normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: SRP-6004 (DB16998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
Study: NCT00445679
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
Study: NCT00066482
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children \< 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
Study: NCT00066482
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children \< 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
Study: NCT00637286
Drug: Zolmitriptan
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg Nasal Spray
Study: NCT01602367
Drug: BMS-823778
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 2 mg, Once daily, 12 weeks
Study: NCT01602367
Drug: BMS-823778
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 6 mg, Once daily, 12 weeks
Study: NCT01602367
Drug: BMS-823778
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 15 mg, Once daily, 12 weeks
Study: NCT01620190
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02239380
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study.
Study: NCT02608216
Drug: ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: therapeutic
Study: NCT02608216
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: therapeutic
Study: NCT03346135
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo standard of care ASCT with a conditioning regimen of melphalan
Study: NCT06461936
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
Study: NCT06461936
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.
Study: NCT03777436
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT00885664
Drug: Truvada (tenofovir/emtricitabine)
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir/emtricitabine fixed dose combination once daily
Study: NCT00885664
Drug: Kaletra (lopinavir/ritonavir)
Normalized name: lopinavir / ritonavir Oral Tablet [Kaletra]
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir 400/100 mg twice daily
Study: NCT00676364
Drug: 4% lidocaine topical anesthetic cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
Study: NCT00903708
Drug: LY2275796
Normalized name: LY2275796
DrugBank: LY2275796 (DB05165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
Study: NCT02782559
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02080780
Drug: 2% Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)
Study: NCT00760045
Drug: Hydroxypropyl Guar Galactomannan
Normalized name: hydroxypropyl guar hydroxypropyltrimonium chloride
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Study: NCT03028909
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care for influenza caused by Type A strains
Study: NCT01311076
Drug: TAK-329
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-329 50 mg, tablets, orally, single dose, one day.
Study: NCT01311076
Drug: TAK-329
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-329 200 mg, tablets, orally, single dose, one day.
Study: NCT01311076
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
Study: NCT00760045
Drug: 0.1% sodium hyaluronate ophthalmic solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Study: NCT00704600
Drug: nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I:~* take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 0: PET-CT~Phase II:~* take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 7 biopsy~* day 7, 21 and week 15 :PET-CT + perfusion CT
Study: NCT00644917
Drug: Xenaderm
Normalized name: Xenaderm
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg under Finn chambers
Study: NCT00758485
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
Study: NCT00758485
Drug: 0.9% sodium chloride (NaCl)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
Study: NCT00005580
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005580
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00232362
Drug: Pioglitazone (Actos)
Normalized name: pioglitazone Oral Tablet [Actos]
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00232362
Drug: Anti-diabetic agent other than pioglitazone or rosiglitazone
Normalized name: INVESTIGATIONAL ANTI-DIABETIC DRUGS
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00627965
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg tds
Study: NCT00004063
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004063
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02299232
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
Study: NCT04054115
Drug: Alprostadil 5 MCG Injection
Normalized name: alprostadil 5 MCG Injection
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
Study: NCT01488383
Drug: Purified extract of Rebaudina Stevia-Stevioside
DrugBank: Stevioside (DB16882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
Study: NCT01488383
Drug: Sodium saccharin
Normalized name: SODIUM SACCHARIN
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
Study: NCT03001635
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
Study: NCT02589626
Drug: empagliflozin 10mg
Normalized name: EMPAGLIFLOZIN 10MG TAB
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02589626
Drug: empagliflozin 25 mg
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00762268
Drug: SAMe
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.
Study: NCT02308891
Drug: lactated Ringer's solution (vigorous hydration arm)
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~* Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~* At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour
Study: NCT02308891
Drug: lactated Ringer's solution (standard hydration arm)
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
Study: NCT05177276
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05177276
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00044629
Drug: zolpidem tartrate (Ambien)
Normalized name: zolpidem tartrate Oral Tablet [Ambien]
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00611572
Drug: iomazenil
Normalized name: Iomazenil
DrugBank: Iomazenil (DB14971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as IV infusion
Study: NCT00611572
Drug: iomazenil
Normalized name: Iomazenil
DrugBank: Iomazenil (DB14971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline IV infusion
Study: NCT04404517
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody used in IBD treatment
Study: NCT04690231
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3
Study: NCT04690231
Drug: ifosfamide and etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ifosfamide and etoposide
Study: NCT00351702
Drug: Isoniazid with Ethambutol
Normalized name: ethambutol / isoniazid
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
Study: NCT00582608
Drug: 131I-8H9
Normalized name: iobenguane (131I)
DrugBank: Iobenguane (DB06704)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\]
Study: NCT00582608
Drug: 8H9
Normalized name: 131-I-8H9 monoclonal antibody
DrugBank: Omburtamab I-131 (DB17124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 50mg/1.73m\^2 of unlabeled 8H9.
Study: NCT00894608
Drug: letrozole + gonadotropins
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
Study: NCT00894608
Drug: GnRHa + gonadotropins
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
Study: NCT02423395
Drug: orphenadrine
Normalized name: Orphenadrine
DrugBank: Orphenadrine (DB01173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orphenadrine in muscle cramps in cirrhotic patients
Study: NCT01539330
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po
Study: NCT00089063
Drug: Montanide ISA 51 VG
Normalized name: Montanide ISA 51 VG
DrugBank: Incomplete Freund's adjuvant (DB17475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT00653458
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ODT, 8 mg, single-dose, fed conditions
Study: NCT00647738
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose 20 mg immediate-release oral tablets